The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).
The VTEUs will contribute to a new federal effort to bolster clinical trial research and the readiness to respond to emerging diseases.
“We are thrilled to continue our work as an NIH-funded vaccine and treatment evaluation unit,” said VVRP director, Dr. C. Buddy Creech, principal investigator of the Vanderbilt VTEU and associate professor of pediatrics.
“Vanderbilt has a rich tradition of vaccine discovery, evaluation and implementation and we look forward to leveraging the remarkable research enterprise at Vanderbilt to advance vaccine science in the United States and around the world,” Dr. Creech said.
Established under the direction of Dr. Peter Wright and continuing under Dr. Kathryn Edwards, Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics, the Vanderbilt VTEU is recognized internationally for its work on vaccines against serious childhood infections including influenza, pertussis, respiratory syncytial virus, Haemophilus influenzae and rotavirus.
In recent years, the Vanderbilt VTEU has pioneered new approaches to evaluate new vaccines, particularly in the area of systems vaccinology, where next-generation sequencing tools are used to characterize the human response to immunization.
The other VTEUs are based at Baylor College of Medicine, Cincinnati Children’s Hospital Medical Center, Emory University, St. Louis University, the University of Maryland, University of Rochester, University of Washington and the Kaiser Permanente Washington Health Research Institute in Seattle.Tags: Friday Letter Submission, Publish on January 24